INM InMed Pharmaceuticals Inc
5,675
$0.3251
$0.0302
(10.24%)
| Watchers | 5,675 |
| 52-Wk Low | $0.2275 |
| 52-Wk High | $2.08 |
| Market Cap | $981,500.00 |
| Volume | 1.78M |
| 52-Wk High | $2.08 |
| 52-Wk Low | $0.2275 |
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease StudiesNewsfile Corp. - News Releases • about 2 months ago
INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathwayIn Vivo studies demonstrate INM-901 reduces neuroinflammation and improves...
Share to Feed
Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and commercialization...
The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Advancing two new preclinical programs in Alzheimer's and Age-Related Macular DegenerationClosed calendar year 2023 with cash position of US$9.5 million164% revenue growth in the commercial BayMedica...
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and...
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ('InMed' or the 'Company'), a leader in the manufacturing, development and...
Advancing INM-901 as a multimodal treatment option for Alzheimer's DiseaseAdvancing INM-089 in the treatment of Age-related Macular DegenerationActively seeking partnerships to advance INM-755 in...